Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma

Cancer

Volumn 101, Issue 3, 2004, Pages 596-603

  Kim, Kevin B ^a   Eton, Omar ^a   East, Mary Jo ^a   Hodges, Cynthia ^a   Papadopoulas, Nicholas E ^a   Grimm, Elizabeth A ^a   Bedikian, Agop Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Concurrent; High dose; Melanoma

Indexed keywords

CISPLATIN; CREATININE; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; ILEUS; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREATITIS; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3242798965     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20403     Document Type: Article

References (22)

1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
2. Chauvergne J, Bui NB, Cappelaere P, et al. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone]. Sem Hop. 1982;58:2697-2701.
3. Costanzi JJ Al-Sarraf M, Groppe C, et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Med Pediatr Oncol. 1982;10:251-258.
4. Luikart SD, Kennealey GT, Kirkwood JM. Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984;2:164-168.
5. Buzaid AC, Legha SS, Winn R. Cisplatin, vinblastine, and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase III Cancer Community Oncology Program (CCOP) trial [abstract]. Proc Am Soc Clin Oncol. 1993;12:389.
6. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
7. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996;7:827-835.
8. Flaherty LE, Robinson W, Redman BG, et al. A Phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer. 1993;71:3520-3525.
9. Atkins MB, O'Boyle KR, Sosman JA, et al. Multiinstitutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994;12:1553-1560.
10. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995;31A:876-881.
11. Gibbs P, Iannucci A, Becker M, et al. A Phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res. 2000;10:171-179.
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17:968-975.
13. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two Phase II Cytokine Working Group trials. J Clin Oncol. 2001;19:3194-3202.
14. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
15. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000;6:3895-3903.
16. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
17. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:708.
18. Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281-283.
19. Ferrazzi E, Toso S, Zanotti M, Giuliano G. Typhlitis (neutropenic enterocolitis) after a single dose of vinorelbine. Cancer Chemother Pharmacol. 2001;47:277-279.
20. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994;69:911-913.
21. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS. Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res. 1996;2:1417-1425.
22. Soubrane C, Mouawad R, Rixe O, Khayat D. Pretreatment serum IL-6 Level as predictive factor of survival in metastatic malignant melanoma patients (MMM) [abstract]. Proc Am Soc Clin Oncol. 2003;22:711.